N/A N=22 Autologous Regeneration of Tissue (ART) for Wound Healing
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=359 Vale+Tú Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19
COVID-19
Primary: Number of Participants Compliant With COVID Vaccination Guidelines as Assessed by a Survey — 30; 28; 33 Participants
N/A N=71 Vaper to Vaper: A Multimodal Mobile Peer Driven Intervention to Support Adolescents in Quitting Vaping
E-cigarette Use · Vaping
Primary: Participant Recruitment and Retention — 37; 31 Participants
Phase 2 N=78 A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Change From Baseline to Day 85 in the Autism Behavior Inventory (ABI) Core Domain Score (Social Communication and Restrictive Behaviour) — -0.20; -0.26 Score on a scale…
N/A N=194 Moving Together: An Online Group Movement Program for People Living With Memory Loss and Caregivers
Alzheimer Disease · Dementia
Primary: Quality of Life - Change (Quality of Life in Alzheimer's Disease Scale, QOL-AD) — -1.7; 0.7 score on a scale — p=0.048
Phase 2 N=219 Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Change From Baseline in ADAS-Cog-11 — 11.05; 0.07; 14.26; 1.04 Change in scale units
Phase 3 N=82 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Gastric Cancer · Gastroesophageal Junction Cancer · HER2-positive Gastric Cancer
Primary: Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0 — 47; 38; 25; 12 Participants
N/A N=16 Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
N/A N=50 EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Breast Carcinoma · Breast Ductal Carcinoma In Situ · Breast Lobular Carcinoma In Situ
Primary: Device Usage
N/A N=29 Cochlear Implant With Dexamethasone Eluting Electrode Array
Sensorineural Hearing Loss · Bilateral Hearing Loss
Primary: Comparison of Monopolar (MP1+2) Impedance Measurement (kOhms) Between Randomization Groups at 6 Months Postoperative — 3.99; 8.66 kOhms
N/A N=53 Stress in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Psychological
Primary: Retention Rate — 23; 25; 19; 22 Participants
Phase 2 N=21 Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Participants With a Response — 2; 2 Participants
Phase 1 N=107 A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
Schizophrenia
Primary: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following MK-8189 Treatment — 4.31; -1.38; -0.61; -1.13 ΔQTcF (msec)
N/A N=110 Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder
Anxiety · Pain · Burnout, Professional
Primary: Mean Change in Visual Analog Scale (VAS) Anxiety Scores — -13.8; -4.7 mm
N/A N=30 Neurolens and Contact Lens Discomfort
Contact Lens Discomfort
Primary: Change in Contact Lens Discomfort — -4.94; -8.67 Scores on a scale